Integra LifeSciences (NSDQ:IART) and Dr. Reddy’s Laboratories (NYSE:RDY) inked an exclusive distribution agreement for the DuraGen Plus and suturable DuraGen Dural Regeneration Matrices in India. According to the deal, Dr. Reddy’s will market and distribute the medical devices throughout India.
The DuraGen Plus Dural Regeneration Matrix is indicated as a dural susbtitute for the repair of dura mater in patients undergoing cranial and spinal procedures. The matrix protects against cerebro-spinal fluid leakage and is fully resorbed and replaced by native tissue, the companies said.
“We are delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery,” Dr. Reddy’s executive VP & head of emerging markets and India biz M.V. Ramana said in prepared remarks.
“Our market-leading DuraGen products have helped more than 1 million patients worldwide,” Integra LifeSciences CFO and corporate VP of international biz Glenn Coleman added. “This collaboration will allow us to continue to expand patient access globally and provide innovative regenerative technology solutions to neurosurgeons and patients in India.”
The suturable DuraGen matrix is a graft that can be sutured and was designed to repair dural defects in patients who require mechanical anchoring of the graft.
Integra said its DuraGen products have been used in more than 1.8 million patients to facilitate dural closure following neurosurgical operations.
